<DOC>
	<DOC>NCT00785512</DOC>
	<brief_summary>This study will evaluate the long-term efficacy of nebivolol monotherapy in patients with stage 1 or stage 2 hypertension after the withdrawal of active medication.</brief_summary>
	<brief_title>A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<criteria>male and female outpatients 18 to 79 years of age Females must be postmenopausal, or not pregnant and using an approved contraceptive regimen meet criteria for stage I or II hypertension currently not treated, or being treated with no more than two antihypertensive medications type 1 or type 2 diabetes secondary hypertension evidence of other concurrent disease or conditions that might interfere with the conduct of the study treatment with any investigational study drug within 30 days of Screening (Visit 1) have a history of hypersensitivity to nebivolol or other βblockers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>nebivolol</keyword>
	<keyword>Bystolic®</keyword>
	<keyword>Hypertension</keyword>
	<keyword>blood pressure</keyword>
	<keyword>withdrawal</keyword>
</DOC>